A new, highly accurate way of proving how new drugs work
Posted: 6 July 2016 | Cold Spring Harbor Laboratory (CSHL) | No comments yet
Researchers have identified a new drug target in AML, created a candidate drug that hits the target and developed a new way of proving how the drug works…
BI-7273 fits precisely in BRD9’s deep bromodomain binding pocket. In preclinical tests, the drug’s binding prevented AML cells from proliferating. CREDIT: Vakoc Lab, CSHL
Researchers have identified a new drug target in acute myeloid leukaemia (AML) and created a candidate drug that hits the target.
Perhaps even more important, the research demonstrates a new, highly accurate way of proving how this and certain other classes of drugs work.
The newly identified target is a binding pocket on a protein called BRD9. The drug designed by BI to bind at that pocket, called a bromodomain, is provisionally called BI-7273.
The team of academic and industry scientists, led by Associate Professor Christopher Vakoc of Cold Spring Harbor Laboratory (CSHL) in coordination with Dr Manfred Koegl of Boehringer Ingelheim, identified BRD9 in screens, then demonstrated its importance in human AML cells grown in culture and in rodent models of AML.
Like nearly all proteins, BRD9 is subdivided into sections called domains, each of which has a specific function. Each domain is encoded by a portion of the BRD9 gene. The domain of interest to Dr Anja Hohmann, who performed the research while still a graduate student in Vakoc’s lab, was BRD9’s bromodomain, the subunit of the protein that “reads” chromatin, a bundled form of the cell’s genetic material.
BRD9’s action necessary for activation of the cancer gene MYC
Experiments led by Hohmann demonstrated that BRD9 is a “dependency” of AML: the human cancer depends on the protein in order to remain capable of proliferating rapidly, unimpeded at the usual checkpoints that cells have evolved to limit growth. Specifically, the team discovered BRD9’s action was necessary for activation of the cancer gene MYC, a master orchestrator of signalling pathways that enable cells to grow uncontrollably.
Boehringer Ingelheim scientists developed several candidate molecules that could bind at the BRD9 protein’s bromodomain. This work led to identification of the compound dubbed BI-7273, which, when tested against AML cells, selectively limited proliferation of the cancer cells, and prevented activation of the MYC oncogene.
Identifying how BI-7273 works
“We were of course pleased with these results,” Vakoc says. “But we set an even higher bar. We wanted to be able to show, unambiguously, how the drug worked – we wanted to prove that its target in AML cells was the bromodomain of the BRD9 protein.” The team’s working hypothesis was that this bromodomain – which forms a deep pocket on BRD9’s surface – is the binding site of the drug BI-7273.
There are various ways of proving that a binding site’s interaction with a drug is the direct cause of the drug’s effect. The most commonly used method is to change the shape or chemical characteristics of the pocket – the binding site, in this case BRD9’s bromodomain – so that the candidate drug can no longer attach there.
The team used structure-guided mutagenesis to determine the precise atomic configuration of the binding pocket and knowledge of how the drug fits into it.
“We figured out a much easier and equally rigorous way of doing this,” Hohmann says, “that exploits the modularity of proteins.” There are 61 known bromodomain “motifs” in at least 48 different proteins, of which BRD9 is one. Using simple copy-and-paste techniques, she and the team “swapped out” the bromodomain of the BRD9 protein and replaced it with the bromodomain that’s part of a protein called BRD4.
A perfect test bed for BI-7273
The team was surprised that the now-modified BRD9 protein continued to function in AML cells. The modified version of BRD9 continued to facilitate the reading of chromatin, and AML cells continued to depend on its action to engage signalling pathways activated by MYC. Cancer cells with the modified BRD9 continued to grow out of control.
This provided a perfect test bed for BI-7273. In AML cells with the “swapped out” BRD9 bromodomain, the drug, as hoped, had no impact on AML proliferation.
“This proved that it was specifically the ‘native’ bromodomain of BRD9 that accounted for the drug’s anti-cancer activity. When we swapped it out, even though the protein continued to function, the drug could no longer attach to it. It’s a very elegant way of showing precisely how the drug had its desired effect, by binding the bromodomain native to BRD9,” Vakoc says.
In other experiments, the team showed the “domain-swapping” technique is “generalisable” in other situations where functionally synonymous domains can be swapped in for domains native to a protein that are thought to be key to a drug’s action. In AML cells, they swapped a domain of the protein EZH2 with a corresponding and functionally synonymous domain from EZH1. Doing so prevented a candidate drug called GSK126, thought to be effective by interacting with wild type EZH2, from impeding the growth of AML cells.